Technology Prognosis

tracking technologies before you have to make a decision

Prognosis is a horizon scanning service that monitors emerging health technologies as they go through clinical trial development and the regulatory approval process.

View a sampling of our Prognosis reports.

SomnaPatch Sleep Apnea Test

July 26, 2017 Technology Prognosis

The SomnaPatch is a home sleep apnea testing device that consists of a forehead-worn disposable adhesive patch connected to a nosepiece. It uses integrated sensors to measure and record nasal pressure, blood oxygen saturation, heart rate, respiratory effort, sleep duration, and changes in body position. The patch weighs less than 1 ounce.

Nerlynx (Neratinib) for Extended Adjuvant Treatment of Breast Cancer

July 20, 2017 Technology Prognosis

Nerlynx (neratinib) is an oral tyrosine kinase inhibitor (TKI) recently approved by the FDA for extended adjuvant treatment of early-stage human epidermal growth factor receptor 2 (HER2)–positive breast cancer in patients who have completed standard adjuvant therapy with Herceptin (trastuzumab). Neratinib blocks signal transduction through the epidermal growth factor receptors (EGFR) HER1, HER2, and HER4. Small-molecule TKI agents may offer advantages over antibody-based HER2 antagonists like Herceptin, such as the ability to cross the blood-brain barrier.

Tisagenlecleucel (CTL019)

July 14, 2017 Technology Prognosis

Tisagenlecleucel is an autologous chimeric antigen receptor (CAR) T-cell therapy that targets the CD19 surface antigen expressed in aggressive B cell malignancies. It is produced by adapting the patient’s own immune cells with tumor antigen recognition and T-cell activation domains. The process of producing tisagenlecleucel begins with collecting peripheral blood mononuclear cells from the patient via leukapheresis. These cells are then sent to a laboratory or a pharmaceutical manufacturing facility where they are genetically engineered to produce CARs on their surface. These reengineered T cells, known as CAR T cells, are able to recognize an antigen on targeted tumor cells....

OTX-DP (Possible Name: Dextenza)

July 13, 2017 Technology Prognosis

OTX-DP is a sustained-release dexamethasone hydrogel punctum plug proposed as an alternative to steroid eye drops for the treatment of ocular pain after ophthalmic surgery. The punctum plug is a rod-shaped biodegradable hydrogel intracanalicular device that delivers 0.4 mg dexamethasone in sustained and tapered release over 4 weeks. The hydrogel is conjugated with fluorescein to enable visualization through eye tissue for plug retention monitoring. OXT-DP is inserted through the inferior punctum following surgery into the operative eye, where it expands and conforms to the inferior distal horizontal canaliculus. It does not require removal after therapy. The device dissolves after remaining...

Kevzara (Sarilumab)

July 11, 2017 Technology Prognosis

Kevzara is an injectable fully human monoclonal antibody directed against the interleukin-6 (IL-6) receptor for the treatment of moderately to severely active rheumatoid arthritis in adults who have had an inadequate response or are intolerant to 1 or more disease-modifying antirheumatic drugs (DMARDs). Proinflammatory cytokines such as IL-6 are linked to the disease process in RA and play a critical role in joint destruction; the IL-6 receptor has been identified as a potential target for RA therapies.